|
|
2025年
| 1. |
Yuki YASUMOTO, Mayu TAKESHITA, Shinsuke INOUE, Yuki TABATA, Yasushi SHIGEMORI, Tomohiro HIKIMA
Function and mechanism of hydrophilic drug-penetration enhancement using ultra-fine water particles on treated skin.
Journal of Drug Delivery Science and Technology, Open access, 112: 107226, 2025.
https://doi.org/10.1016/j.jddst.2025.107226
|
2024年
| 1. |
Natsumi AMANO, Yuusei TAKAKI, Harunori TAKEI, Masaaki MATSUO, Masaya HARA, Yasunori TASHIRO, Takahiro ONIKI, Takahiro ITO, Tomohiro HIKIMA
Fabrication and mechanical/biological evaluations of dissolving bird-bill microneedle arrays.
Drug Delivery and Translational Research, Open access, 15: 2581-2588, 2025
https://doi.org/10.1007/s13346-024-01757-w
|
2023年
| 3. |
森大輔、引間知広
第6章 経皮吸収シミュレーションソフトウェア(SKIN-CAD)
動物実験代替法とNew Approach Methodsの開発・利用動向
シーエムシー出版, 2023年9月. (in Japanese)
ISBN: 978-4-7813-1747-2
|
| 2. |
Tomohiro HIKIMA, Haruhiko EZAKI
Predicting the safety of ocular iontophoresis using reconstructed human corneal epithelial cells.
Biological and Pharmaceutical Bulletin, 46(7): 1021-1023, 2023
https://doi.org/10.1248/bpb.b23-00096
|
| 1. |
Yasuhiro MORI, Akifumi YAMAMOTO, Ayumi NAKAGAWA, Tomohiro HIKIMA, Akiharu ISOWAKI
Potential of TAK-593 ophthalmic emulsion for the treatment of age-related macular degeneration
Biological and Pharmaceutical Bulletin, 46(7): 921-928, 2023
https://doi.org/10.1248/bpb.b23-00066
|
2022年
| 1. |
Toma SAKAI, Nanami SODEMOTO, Asako INOUE, Suguru TANIGUCHI, Iori MAEDA, Tomohiro HIKIMA
Suitability of high-molecular-weight tissue-derived elastin polypeptides and their particles as cosmetic biomaterials.
Journal of Peptide Science, 29(6): e3472, 2023.
https://doi.org/10.1002/psc.3472
|
2021年
| 2. |
Yuki MIZUNO, Kanae TAKASAWA, Taichi HANADA, Kyou NAKAMURA, Kazuya YAMADA, Hirotaka TSUBAKI, Masaya HARA, Yasunori TASHIRO, Masaaki MATSUO, Takahiro ITO, Tomohiro HIKIMA.
Fabrication of novel-shaped microneedles to overcome the disadvantages of solid microneedles for the transdermal delivery of insulin.
Biomedical Microdevices, 23(3): 38, 2021.
https://doi.org/10.1007/s10544-021-00576-x
|
| 1. |
Junsaku KITAGAWA, Hayato ARAI, Hiroyuki IIDA, Jiro MUKAI, Kenji FURUKAWA, Seitaro OHTSU, Susumu NAKADE, Tomohiro HIKIMA, Miwa HARANAKA, Naoto UEMURA.
A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19.
Clinical and Translational Science, 14(5): 1967-1976, 2021.
https://doi.org/10.1111/cts.13052
|
|
まで